News

Biotech's Boom Suffers a Setback in March April 01, 2014 | Press Release

Investors Flock to Biotech March 03, 2014 | Press Release

Biotech IPOs Off to a Strong Start in 2014 February 03, 2014 | Press Release

  See all News
 
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.


Burrill & Company announces promotions

April 10, 2009

FOR IMMEDIATE RELEASE
 
Contact: Peter Winter, Editorial Director
Burrill & Company Tel: 415-591-5474
Email: pwinter@b-c.com
       
SAN FRANCISCO, April 9, 2009 - Burrill & Company, a San Francisco based global leader in the life sciences with principal activities in Venture Capital, Private Equity, Merchant Banking and Media, is pleased to announce the following staff promotions:
- Tiba Aynechi to Director, Merchant Banking
- Garrett Vygantas, Director, Venture Capital
- Neel Patel to Senior Associate, Merchant Banking
 
Tiba Aynechi joined Burrill Merchant Banking in 2006 following an internship in the Venture Group. Previously, Tiba was a postdoctoral fellow at the University of California, San Francisco, developing computational models for drug discovery. She received her Ph.D. from the Graduate Group in Biophysics at the University of California, San Francisco.
 
Garrett Vygantas - Before joining Burrill in 2006, Garrett was with Genentech’s Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of wet age-related macular degeneration. Dr. Vygantas completed his Transitional Residency at the University of Pennsylvania and holds M.D. and MBA degrees from Georgetown University. He is a co-founder and interim CEO of NewBridge Pharmaceuticals and serves on its Board of Directors. He is a Board Observer of Nora Therapeutics, Proventys, Ikano Therapeutics, ProteoGenix, and NanoVasc.
 
Neel Patel has broad advisory experience across life sciences coupled with functional experience in post-merger integration, turnaround management, operations and strategic planning. Neel was a management consultant with A.T. Kearney where he focused on strategy and operations consulting. He also worked in business development at Roche Diagnostics. He has an MBA from the University of Chicago Graduate School of Business.
 
"Our Merchant Banking and Venture Capital Practices continue to perform very well despite the difficult economic climate that we are currently facing. The promotions are reflective of the excellent contributions that these three individuals have made,” said, G. Steven Burrill, CEO, Burrill & Company.
 
  
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the Burrill Report (www.burrillreport.com), which tracks the progress of the global biotechnology industry; the Burrill Report Weekly Brief, and annual “State of the Industry” report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd report on the industry. This book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond (www.burrillandco.com/Biotech2009)
 
 
                                                            ###

Back to News list  
News Archive: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All